Sanofi-backed Formation Bio raises $372 million in late-stage funding round
June 26 (Reuters) -AI-based drug developer Formation Bio said on Wednesday that it has raised $372 million in a late-stage funding round, with a significant participation from French drugmaker Sanofi SASY.PA.
The funding was led by venture capital firm Andreessen Horowitz, Sequoia and FPV Ventures among others.
WHY IT'S IMPORTANT
Easing inflationary pressures, increasing bets of a soft landing for the U.S. economy and promising data from drug trials are starting to boost the biotech funding market, which saw a downturn last year along with other industries.
Major drugmakers are using artificial intelligence to find patients for clinical trials quickly, or to reduce the number of people needed to test medicines, both accelerating drug development and potentially saving millions of dollars.
CONTEXT
Formation Bio partners, acquires, or in-licenses drugs from biotech and pharma companies and then it develops those programs using its proprietary technology platform.
The company plans to allocate the new capital towards two primary objectives - acquiring and in-licensing drug candidates and expanding its AI capabilities.
Last month, Sanofi announced that it is collaborating with OpenAI and Formation Bio to boost its drug development projects through the use of artificial intelligence.
BY THE NUMBERS
The company, which did not disclose the valuation of the latest round, raised $372 million in Series D funding, a "material step up" from its previous valuation of $1 billion.
The company previously raised $156 million in its last funding round in 2021.
Reporting by Sneha S K in Bengaluru; Editing by Alan Barona
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
